CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting

• Published in: Journal of hematology & oncology Vol. 16; no. 1; p. 18
• Main Authors: Huang, Qiusha, Zhang, Xiao-Hui, Liu, Delong
• Format: Journal Article Conference Proceeding
• Language: English
• Published: England BioMed Central Ltd 05.03.2023; BioMed Central; BMC
• Subjects: Antigens; Antimitotic agents; Antineoplastic agents; Biomarkers; Cancer; CAR T; Care and treatment; CD3; CD3 antigen; CD7; CD7 antigen; Cell surface; Cell therapy; Clinical trials; Correspondence; Cytokines; Genomes; Genomics; Graft versus host disease; Hematology; Humans; Immunotherapy, Adoptive; Leukemia; Leukemia, T-Cell; Lymphocytes; Lymphocytes T; Lymphoma; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Lymphomas; Malignancy; Neurotoxicity; Oncology; Protein expression; Proteins; Response rates; Stem cells; T cell leukemia; T cells; CD3; T cell leukemia; Lymphoma; CAR T; CD7
• ISSN: 1756-8722; 1756-8722
• DOI: 10.1186/s13045-023-01406-8

Due to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags behind that for B cell malignancies. Attempts are being made to revise T cell biomarkers so that the re-engineered CAR T cells can target T cell malignancies. CD3 and CD7 are the two pan-T cell surface biomarkers that have been either knocked out or knocked down through genome base- editing technology or by protein expression blockers so that the re-engineered T cells can target T cells without fratricide. We summarized several latest reports on the CAR T cells for the therapy of T cell leukemia /lymphoma from the 2022 ASH Annual Meeting, with latest updates on clinical trials of TvT CAR7, RD-13-01, and CD7 CART.